Previous Article | Next Article 
Infection and Immunity, February 2000, p. 744-751, Vol. 68, No. 2
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Absence of SpeB Production in Virulent Large
Capsular Forms of Group A Streptococcal Strain 64
Roberta
Raeder,1
Evlambia
Harokopakis,2
Susan
Hollingshead,2 and
Michael D. P.
Boyle1,*
Department of Microbiology and Immunology,
Medical College of Ohio, Toledo, Ohio
43613-5806,1 and Department of
Microbiology, University of Alabama Birmingham, Birmingham, Alabama
352942
Received 26 August 1999/Returned for modification 6 October
1999/Accepted 28 October 1999
 |
ABSTRACT |
Passage in human blood of group A streptococcal isolate 64p was
previously shown to result in the enhanced expression of M and
M-related proteins. Similarly, when this isolate was injected into mice
via an air sac model for skin infection, organisms recovered from the
spleens showed both increased expression of M and M-related proteins
and increased skin-invasive potential. We show that these phenotypic
changes were not solely the result of increased transcription of the
mRNAs encoding the M and M-related gene products. Rather, the altered
expression was associated with posttranslational modifications of the M
and M-related proteins that occur in this strain, based on the presence
or absence of another virulence protein, the streptococcal cysteine
protease SpeB. The phenotypic variability also correlates with colony
size variation. Large colonies selected by both regimens expressed more
hyaluronic acid, which may explain differences in colony morphology.
All large-colony variants were SpeB negative and expressed three
distinct immunoglobulin G (IgG)-binding proteins in the M and M-related
protein family. Small-colony variants were SpeB positive and bound
little IgG through their M and M-related proteins because these
proteins, although made, were degraded or altered in profile by the
SpeB protease. We conclude that passage in either human blood or a
mouse selects for a stable, phase-varied strain of group A streptococci
which is altered in many virulence properties.
 |
INTRODUCTION |
Group A streptococci cause a wide
range of human disease ranging from mild throat and skin infections to
serious and life-threatening conditions of necrotizing fasciitis and a
toxic shock-like syndrome (23, 58, 60). A number of
potential virulence factors have been identified in different studies.
These include surface M and M-related proteins (9, 45),
fibronectin-binding proteins (43, 63), the hyaluronic acid
capsule (18, 41, 56, 64), and a number of secreted products
including the cysteine protease SpeB (17, 26-29, 33-35),
streptokinase (37), and a variety of phage-encoded exotoxins
(57).
Depending on the isolate studied and/or the model system used for
virulence studies, the significance of a given putative virulence
factor can vary from being great to nil. In many studies the
antiphagocytic M protein has been shown to be the critical virulence
factor (9, 45), while in other studies the hyaluronic capsule was found to be responsible for virulence irrespective of M
protein expression (18, 64).
Similar differences have been noted in studies of the importance of
SpeB in mouse infection models. Studies by Lukomski et al.
(33-35) and others (29) provide evidence for
SpeB as a virulence factor, while studies from our laboratory using a
skin infection model (49, 50, 52) and studies by Ashbaugh et
al. (2) in mouse model of intraperitoneal infection indicate
that SpeB expression is not directly associated with a more virulent
phenotype. These differences may reflect differences in isolates
studied or in the precise animal model being used.
Interpretation of these divergent findings is further complicated by
the observation that SpeB can modify other virulence factors such as
streptolysin O (44) or M protein (6, 19, 53) to
either increase or decrease their biological activities, respectively.
In addition, cysteine protease can affect host receptors, activate
cytokines, and metalloproteinases, and trigger various homeostatic
pathways (14, 22, 27, 58, 65) and can potentially induce
autoimmune postinfection sequelae (17) as well as influence invasion of epithelial cells (62).
Expression of virulence genes can also vary in cultured streptococci
(7, 16, 38-40), and phenotypic changes in response to
biological selection pressures in human blood or in mice are also well
established (49, 50, 54). These phase variations as well as
differences in genetic background could influence the effectiveness of
a given putative virulence gene (45). Furthermore, preexisting immunity and difference in efficiency of innate immune responses in the host can also contribute to the outcome of the infection (23).
Our laboratory has studied one group A isolate, 64, extensively and
found that stable phenotypic variants expressing enhanced surface
immunoglobulin G (IgG)-binding proteins can be selected either in human
blood or by passage in mice (49, 50, 54). These variants
were found to be stable on subsequent subculture in the laboratory, in
the absence of any biological selection pressure, for a period of over
5 years. Selected variants were clearly demonstrated to be more
virulent when tested in a mouse model of skin infection (49,
50).
The selection of these stable variants of isolate 64 was not an
all-or-nothing event but required multiple blood passages or passages
in mice (49, 50, 54). In particular, the changes in
expression of M and M-related IgG-binding proteins in isolate 64 passaged in human blood followed an interesting pattern. The parent
isolate, 64p, expressed a predominant IgG-binding activity associated
with the mrp gene product. Following sequential passage, three antigentically distinct IgG-binding proteins were identified. One
is the Mrp protein expressed by the parent isolate; the other two
IgG-binding proteins were found to be the products of the emm and enn genes (13). All three of
these genes encoding IgG-binding proteins are known to be present in
the coordinately regulated mga regulon. Thus, the pattern of
differential gene expression between the parental strain and the
strains derived from the mouse or human blood passage was intriguing.
In this study we have examined different selected variants of isolate
64 that demonstrate distinct IgG-binding protein phenotypes to
determine the nature of the regulation that leads to the various IgG-binding phenotypes.
 |
MATERIALS AND METHODS |
Solubilization of IgG-binding surface proteins.
Proteins
reactive in a nonimmune fashion with human immunoglobulins were
extracted from the bacterial surface by treatment with CNBr as
previously described (48). This procedure has been shown to
be an efficient method to solubilize IgG-binding proteins from group A
streptococci and results in solubilization of three distinct
IgG-binding proteins from isolate 64/14 (13, 47).
Plasma proteins.
Human IgG1, IgG2, and IgG4 myeloma proteins
were obtained from Calbiochem (San Diego, Calif.). Human IgG3 myeloma
cryoglobulin was a gift from Richard Weber.
Labeling of proteins.
Human IgG1, IgG2, and IgG4 were
labeled with horseradish peroxidase (HRP) by using an HRP labeling kit
(Zymed Laboratories, San Francisco, Calif.). Human IgG3 cryoglobulin
was labeled with biotin by using biotin-N-hydroxysuccinimide
ester (Calbiochem, La Jolla, Calif.) according to the method of Bayer
and Wilchek (4).
Analysis of IgG-binding proteins.
CNBr-extracted surface
proteins, or sonicates of Escherichia coli containing
recombinant proteins, were denatured and electrophoresed in 12%
polyacrylamide minigels for 45 min at 200 V according to the method of
Laemmli (30). Prestained molecular weight markers (low
range; Bio-Rad, Richmond, Calif.) were included on each gel.
Following electrophoresis, separated polypeptides were transferred to
nitrocellulose (Bio-Rad) by electroblotting as described elsewhere
(61) and incubated with an appropriate dilution of the
indicated labeled probe. Nitrocellulose membranes probed with biotinylated probes were again washed and then reprobed with
HRP-labeled streptavidin (Amersham Life Sciences, Chicago, Ill.). The
membranes were developed by using an ECL (enhanced chemiluminescence)
Western blotting kit (Amersham Life Sciences, Chicago, Ill.) according to the manufacturer's instructions and exposed to Kodak XAR-5 film for
5 to 60 s at ambient temperature.
Analysis of transcription of IgG-binding protein genes.
RNA
was purified from 1 g (wet weight) of washed cells for each strain
grown to an approximate optical density of 0.6 at 600-nm wavelength.
RNA purification and Northern analysis were performed by methods
described previously (66). The probes used for Northern hybridization were PCR-generated fragments containing only
gene-specific regions of the three genes in the emm gene
cluster of strain 64. These probes included bp 181 to 1091 of the SF4
gene (mrp64), 1643 to 2036 of the SF2 gene
(emm64), and 3215-3472 of the SF3 gene (enn64)
(13). Primers for probes were the following: mrp, 5'GGATCCCCGGGCATCCGTAGCAGTCGCT3' and
5'TTCTTGGTTGGTTGCTGCTAATT3'; emm,
5'AATCTGCAGTATTCGCTTAGAAAATTAAAA3' and
5'CCTAAAAGATTCCTATTAAGTCTA3'; enn,
5'ATGGCTAGCCACAACCAAGAAAAAT3' and
5'GTTCTTGATAACGTTTTTCTACTTCTCG3'; and recA,
5'ACGAACGTCGAAAGCCCTTG3' and
5'CGGTTTCTTCTGATGCTACTGCC3'.
Experimental procedures for labeling probes, running gels, and
quantifying transcripts were previously described; results are reported
as a simple ratio of M-related gene transcript over recA
transcript on the same blot after correction for probe length and
exposure time (66). The recA gene transcript is
produced constitutively and has been shown to remain stable under
conditions of the experiment (40). Thus, recA
transcript is used as an internal control for RNA yield and loading.
This control allows the comparison of relative levels of
mrp, emm, and enn transcripts from
strains emanating from each passage.
Isolation of extracellular streptococcal cysteine protease.
A cysteine protease was isolated from culture supernatants by a
modification of the method described in reference
19. Isolate 64p was grown to stationary phase for
24 h at 37°C in Todd-Hewitt broth (THB). Centrifugation and
filtration of the culture supernatant removed bacteria through a
0.22-µm-pore-size filter. The filtered culture supernatants were
brought to 80% saturation with ammonium sulfate. Precipitated material
was recovered by centrifugation at 4,000 × g for 20 min at 4°C. The pellet was resuspended in distilled water equal to
1% of the original culture volume and dialyzed extensively against
distilled water. Preparations demonstrating proteolytic activity
contained a single Mr-~27,000 band in
Coomassie blue-stained sodium dodecyl sulfate (SDS)-polyacrylamide gels.
Assay for functional cysteine protease activity.
Cysteine
protease activity present in ammonium sulfate-precipitated culture
supernatants was assayed following extensive dialysis against
phosphate-buffered saline according to the method of North (42). Briefly, 50 µl of the concentrated culture
supernatant, without or with 0.1 mM dithiothreitol, was added to wells
of a microtiter plate. Following incubation for 30 min at 37°C, to allow for reduction of the enzyme, 150 µl of substrate-buffer solution was added to each well. The substrate-buffer solution consisted of 3.2 ml of 2.5 mM Benz-Pro-Phe-Arg-paranitroanilide (Sigma)
dissolved in pH 4.0 distilled water plus 4.8 ml of 0.1 M sodium
phosphate, pH 6.0. Cleavage of the substrate was monitored by measuring
the A405 over time in a microtiter plate reader
(BioTek, Winooska, Vt.). The cleavage of substrate and generation of
product were determined to be linear with time to an
A405 of 1.5. The cysteine protease-specific
inhibitor E64 (Sigma) was included in parallel assays at a
concentration of 1 µM to determine if all of the enzyme activity
being measured could be attributed to the presence of a cysteine
protease (3).
The antigenic form of SpeB was determined by Western blotting using a
polyclonal antiserum to SpeB (Toxin Technologies, Sarasota, Fla.).
Antibody bound to active SpeB (Mr ~ 27,000) or the zymogen form of SpeB (Mr ~ 48,000) was detected with a protein G-HRP reporter system. In all
experiments, a parallel blot was probed with normal rabbit serum to
control for any nonspecific binding proteins that might be present.
Treatment of recombinant proteins with SpeB.
Sonicates of
E. coli expressing recombinant Emm64, Mrp64, or Enn64
protein were incubated at 37°C for the times indicated with the
cysteine protease prepared from the culture supernatant of strain 64p
in the absence or the presence of 1 µM E64. The reaction was stopped
by the addition of SDS sample buffer and heating for 10 min at 100°C.
Enzyme digests were resolved on SDS-polyacrylamide gels, electroblotted
to nitrocellulose, and probed with labeled human IgG1 and IgG3. The
blots were developed by using the Amersham ECL reporter system and
exposed to Kodak XAR film for 5 to 60 s.
Casein overlay plate assay for detection of protease
production.
Todd-Hewitt agar plates containing 100 to 200 individual colonies were overlaid with 5 ml of 0.8% agarose containing
1% skim milk and 1 mM dithiothreitol. Hydrolysis of casein was
determined by examining plates for zones of clearing around individual
colonies following 4 h of incubation at 37°C. Overlays were
performed in duplicate in the absence or the presence of 1 µM E64 to
ensure that casein hydrolysis was due to a cysteine protease.
Analysis of hyaluronic acid capsule.
Capsular hyaluronic
acid was determined by a chemical method as described previously
(64).
 |
RESULTS |
Analysis of effects of biological pressure on expression of M and
M-related proteins.
The pattern of expression of the M and
M-related IgG-binding proteins varies as a function of blood or mouse
passage. In the parent isolate (64p), a significant level of the Mrp
gene product is identified, with no protein product from the
emm or enn genes being detectable in CNBr
extracts (Fig. 1). Following extensive passage of isolate 64 in human blood (64/14bp) or in mice (64/14sk), a
variant which demonstrated changes in the profile of Emm- and Enn-binding proteins present in CNBr extract was selected (Fig. 1). In
addition, quantitative changes in IgG binding were observed (Table
1).

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 1.
Western blot analysis of the heterogeneity of
IgG-binding proteins in CNBr extracts of various blood- and
mouse-passaged isolates of strain 64. The upper and lower panels were
probed with IgG1 and IgG3, respectively, as described in Materials and
Methods. Samples were adjusted for approximately equivalent
IgG1-binding activity. For quantitative differences in IgG-binding
proteins among bacterial variants, see Table 1.
|
|
To determine whether the differences in IgG-binding protein expression
corresponded to changes in mRNA levels in the biologically selected
isolates, quantitative Northern blotting analysis was performed. Total
RNA was recovered from bacterial populations of isolate 64 following 1, 3, 7, 9, or 23 sequential blood passages or passage through mouse skin
and recovery from the spleen (64/14sk2 and -3). The purified RNA was
probed for the presence of message for each M and M-related protein and
compared to message for recA in the same RNA preparation as
an internal control for RNA recovery.
The results presented in Table 2
demonstrate that emm and mrp messages were
roughly equivalent in all variants despite the major differences in the
corresponding proteins associated with variants (Fig. 1 and Table 1).
In the parental isolate, the enn gene (encoding an
Mr-~32,000 IgG3-binding protein) was not
transcribed as actively as the emm or mrp gene
(encoding Mr-~50,000 and
Mr-~35,000 IgG1-, IgG2-, and IgG4-binding
proteins, respectively). However, following passage of this isolate
through human blood on nine or more occasions, the level of
enn message increased (Table 2). This increase in
enn gene expression is accompanied by increased levels of
the Mr-~32,000 IgG3-binding Enn protein in
CNBr extracts (Fig. 1). Thus, the differences in Enn protein expression
among variants could be related, at least in part, to regulation at the
transcriptional level.
An increase in transcriptional levels, however, would not account for
the differences in expression of Emm and Mrp proteins (Fig. 1 and Table
1) compared to message levels of the corresponding genes shown in Table
2. Taken together, the data suggest that some form of posttranslational
modification of Emm and/or Enn might contribute to the IgG-binding
phenotypes of the variants detected in CNBr extracts.
Previous studies of IgG-binding protein expression by M1 isolates had
identified an effect of a cysteine protease SpeB on the quantity and
immunoglobulin-binding properties of the IgG-binding M1 protein
(51, 53). Consequently, in the next series of experiments the production of SpeB by the blood- and mouse-passaged variants of
isolate 64 was tested. This analysis was carried out both for expression of functional enzyme in a synthetic substrate assay and for
protein production as measured by Western immunoblotting. This latter
approach had the advantage of detecting production of both active
enzyme (Mr ~ 28,000) and the zymogen form
of SpeB (Mr ~ 48,000). In all of these
studies, only the low-Mr form of SpeB was
detected. If the cultures were grown in the presence of iodoacetic
acid, the zymogen form of SpeB was readily detectable (data not shown).
The results of this analysis demonstrated differences in the production
of SpeB between parental and passaged isolates. In the parent and early
blood passages of isolate 64 (bp3, bp7, and bp9), there was a
demonstrable quantity of the active form of SpeB detected in culture
supernatants by both antigenically and functional assays. SpeB protein
could not be detected in the culture supernatants of isolates that had
been passaged in human blood on more than 12 occasions (Table 1).
Isolates that had SpeB activity could be completely inhibited by
addition of 1 µM E64, a cysteine protease inhibition (3). Growth in the presence of the inhibitor also correlated with a shift in
the expression pattern for IgG-binding proteins Mrp, Emm, and Enn
(Table 1). When this isolate was grown in the absence of E64, the CNBr
extracts contained a lower quantity of IgG-binding activity and a
markedly different profile. Under these culture conditions, the
emm gene product and the enn gene product were markedly reduced or absent, while minimal change was observed for the
mrp gene product (Table 1). These results suggest that SpeB
might degrade Emm and Enn proteins while having minimal effects on Mrp.
To test the hypothesis that SpeB protease activity was involved in
posttranslational modification of M and M-related proteins, recombinant
Emm 64/14, Mrp 64/14, or Enn 64/14 was incubated with cysteine protease
prepared from the culture supernatant of isolate 64p as described in
Materials and Methods. The results of these studies indicated that the
cysteine protease could preferentially destroy recombinant Emm and Enn
protein while the Mrp protein was relatively resistant to degradation
with the enzyme (Fig. 2). These studies
provide an explanation for the differences in surface IgG-binding
protein profiles for isolates grown in presence or absence of the
cysteine protease inhibitor E64 (Table 1).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 2.
Treatment of recombinant Emm, Mrp, or Enn 64 with a
streptococcal cysteine protease and effect on IgG-binding properties.
Sonicates of E. coli expressing recombinant Emm, Mrp, or Enn
protein were incubated at 37°C for the times indicated with the
cysteine protease prepared from the culture supernatant of strain 64p.
The reaction was stopped by addition of sample buffer and boiling. The
immunoglobulin reactivity remaining following immunoblotting was
measured as described in Materials and Methods. Blots were developed by
an ECL procedure and exposed to Kodak XAR film for 30 to 60 s.
|
|
Isolate 64, following nine passages in human blood (64/bp9),
demonstrated a change in the profile of IgG-binding proteins, with all
three IgG-binding proteins being detectable (Table 1). The IgG-binding
profiles in CNBr extracts of these isolates were intermediate between
those for the parental (64p) and an extensively mouse selected variant
(64/14sk) or a variant selected following 12 or more sequential
passages in human blood (64/bp12) (Table 1).
To determine whether this effect was due to a mixed population of
cysteine protease-positive and -negative organisms within the
population, individual colonies of isolate 64/bp9 were grown on
Todd-Hewitt agar and replica plates overlaid with casein with or
without E64 to detect cysteine protease-producing colonies. In this
assay, two distinct phenotypes of casein hydrolysis could be
distinguished. One group of colonies failed to cause casein hydrolysis,
while the second group showed efficient clearing of casein around the
colonies. This activity was dependent on production of a cysteine
protease, since inclusion of E64 totally inhibited the activity.
In addition to differences in cysteine protease production, bacteria
grown on Todd-Hewitt agar plates showed two morphologically distinct
types of colonies (Fig. 3A). These
colonies could be separated and maintained their morphological
characteristics (Fig. 3B and C). The small and large colonies were
analyzed for hyaluronic acid content, and small colonies were found to
contain <50% of the hyaluronic acid content of the large variants.
This was consistent with the colony size morphology being the result of
a phase variant in capsular content. When tested for production of a
casein-hydrolyzing enzyme by using a casein overlay technique, all of
the small colonies were positive, while no hydrolysis was observed
surrounding the large colonies. Studies using E64 and analysis of
antigenic SpeB protein expression confirmed that the casein hydrolysis
associated with the small colonies was mediated by SpeB. The large
colonies failed to secrete either the zymogen or active form of SpeB
(data not shown).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 3.
Colonial morphology of strain 64p following passage
through human blood on nine consecutive occasions. A stationary culture
of blood-passaged strain 64/bp9 was diluted in phosphate-buffered
saline and spread on Todd-Hewitt agar. Following overnight incubation
at 37°C, plates with ~100 colonies were examined for colonial
morphology. (A) Day 9 of blood passage demonstrating the presence of
two colony types; (B) a small colony selected and expanded from the
plate in panel A. The small-colony variants secreted an E64-inhibitable
cysteine protease that led to hydrolysis of overlaid casein. (C) A
large colony selected and expanded from the plate in panel A. The
large-colony variants did not generate a cysteine protease.
|
|
Representative small and large colonies were expanded in culture, and
their surface IgG-binding proteins were analyzed following CNBr
extraction. The IgG-binding protein profile of the cysteine protease-producing small isolates was similar to that of extracts of
the parent 64p isolate, while those extracted from the larger, cysteine
protease-negative colonies demonstrated the IgG-binding profile of the
extensively mouse- or blood-passaged isolates (Fig. 4). Analysis of individual colonies of
bacteria recovered following extensive passage of isolate 64 through
human blood on 12 or more occasions consisted entirely of the
large-colony phenotype, and all colonies failed to produce cysteine
protease activity. These observations suggest that isolates with the
large-colony morphology were stable.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Immunoglobulin-binding reactivity of surface proteins
expressed by representative small and large colonies. Single-colony
isolates of blood-passaged strain 64/bp9 demonstrating either the
small- or the large-colony morphology were grown to stationary phase in
THB. Surface proteins following extraction with CNBr were separated by
SDS-PAGE, electroblotted to nitrocellulose, and probed as indicated. A
representative extract from the parent isolate 64p and an extract from
the isolate passaged 14 times in mice (64/14) are included for
reference. Blots were developed by an ECL procedure and exposed to
Kodak XAR film for 30 to 60 s.
|
|
To test this prediction, three arbitrarily selected colonies of either
the small- or large-colony morphology were passaged in THB and screened
for morphological type and cysteine protease activity following each
passage. The results of these studies (Table
3) demonstrate that the large colonies
retained their morphological appearance and high level of hyaluronic
acid capsule on subculture. By contrast, there was a significant and
measurable rate of conversion from small colonies to large colonies
with concomitant loss of cysteine protease activity and acquisition of
a larger hyaluronic acid capsule (Table 3).
The resulting large colonies selected from the small colonies in these
experiments retained their morphology and lack of secretion of cysteine
protease on subculture on 10 additional occasions. This finding
suggests that the cysteine protease-negative, large-colony phenotype is
more stable. Growth of small colonies in the presence of E64 failed to
convert them to large colony types. Similarly, incubation of large
colonies with purified SpeB failed to convert them to small colonies.
These results suggest that the association between capsule production
and SpeB activity cannot be attributed to a direct effect of the enzyme
activity on a capsule synthetic pathway but would be consistent with
some form of coregulation of gene expression.
 |
DISCUSSION |
Regulation of expression of virulence factors by
Streptococcus pyogenes is complex. In addition to multiple
serotypic and genetic variation in group A isolates (7-12,
23), phenotypic variation can occur as a result of
transcriptional control of individual virulence genes (16, 20,
38-40) as well as through posttranslational modification of
exposed proteins by bacterial proteases like SpeB (6, 53,
58). SpeB expression can, in turn, be regulated by the
rgg gene (16) and potentially influenced by the
activity of the oligopeptide permease and transport mechanisms (36, 46). In addition, our laboratory has described a global regulating gene, pel, which can influence secretion of SpeB
as well as influencing surface M and M-related proteins
(32).
It is also clear from many in vitro and in vivo studies of group A
isolates that either M protein or the hyaluronic acid capsule can play
a direct role as a major virulence factor 2, 18, 41, 55,
56; C. D. Ashbaugh, M. H. Shearer, R. C. Kennedy, G. C. White, and M. R. Wessels, Abstr. 99th Gen.
Meet. Am. Soc. Microbiol. 1999, abstr. D/B-160, p. 240, 1999). Recent
studies on the regulation of capsule synthesis by a number of
investigators have identified a two-component regulatory system
(1, 5, 20). This regulatory activity may also control
additional phenotypic characteristics of the organism, possibly
including SpeB (21). At this time, the nature of the sensory
signal triggering the two-component system has not been described.
In this study we have observed variants of isolate 64 in which SpeB, M,
and M-related proteins and capsular phenotype could vary. These
variants were selected by passage of group A isolate 64 in human blood
or mice. Although the precise biological pressure responsible for
selecting the variant forms has not been identified, similar phenotypes
were selected in each of the biological systems. The results summarized
in Table 1 demonstrated that SpeB-positive variants expressed lower
levels of Emm and Enn relative to Mrp, while the SpeB-negative variants
showed approximately equivalent levels of all three IgG-binding
molecules. Analysis of the differences indicates that SpeB could
degrade the Emm and Enn proteins while having minimal effect on Mrp
(Fig. 2). Comparison of SpeB-producing and nonproducing isolates also
demonstrated significant differences in capsule morphology.
SpeB-negative variants were associated with a larger capsule than their
isogenic SpeB-positive variants (Fig. 3).
Taken together, all of our observations suggest that biological
pressures in human blood or in a mouse can select for a phase variation
that shifts a small-capsule, SpeB-positive bacterium into a
large-capsule, SpeB-negative bacterium. The SpeB-negative large-colony
variant of isolate 64 appears to be better adapted to survival against
biological pressures in either human blood or in mice. Whether the
small-colony variant has a superior adaptive capability within a
different environment is not known.
Leonard et al. recently described small- and large-colony variants of
M2 and M49 isolates (31). The small-colony types were associated with high-density, low-nutrient-flow conditions that exist
in prolonged stationary-phase cultures. In their study, the
small-colony variants were found to be deficient in Mga and gene
products under its control. For isolate 64, small-colony variants
produced equivalent or greater levels of transcript from genes in the
mga region. Furthermore, the large-colony variants of the M2
and M49 isolates derived under nutrient-poor conditions produced SpeB,
while the large-colony variants of 64, selected by biological pressure
in human blood or in mice, failed to secrete either the zymogen or
functionally active enzyme. In both cases, however, the large-colony
variant appeared to be more stable than the small-colony variant under
nutrient-rich conditions.
Analysis of the different variants in a mouse model of skin infection
demonstrates that the SpeB-negative, large-capsule form is more
invasive (52). Thus, SpeB expression is associated with decreased virulence potential in this system. Since SpeB can
posttranslationally degrade surface M proteins on strain 64 (53), the decreased invasive potential may be indirectly
attributable to the small amount of capsule or the loss of M protein,
or possibly a combination of the two. Studies by Wessels and colleagues
on the role of hyaluronic acid capsule or M protein expression in the
virulence of isogenic streptococcal strains in mouse and baboon models
are in basic concordance with the direction of virulence potentiation
reported here (2, 41, 64; Ashbaugh et al., Abstr. 99th
Gen. Meet. Am. Soc. Microbiol.). They reported that a large capsule and
the presence of M protein both increase virulence potential. In the studies by Wessels and colleagues, the presence or absence of SpeB did
not vary the virulence potential of an isolate.
Lukomski and colleagues (33-35) and others (29)
also performed studies using SpeB-negative isogenic mutants and found
that SpeB-expressing strains were more virulent than their
SpeB-negative counterparts. Vaccination of mice with SpeB could also
prevent subsequent death following a lethal infection in this case
(26). In contrast with our findings and those of Wessels and
colleagues (2, 41, 64; Ashbaugh et al., Abstr. 99th Gen.
Meet. Am. Soc. Microbiol.), the findings of Lukomski et al. suggested a role for SpeB in increasing the virulence potential of the associated strain. Lukomski et al. also demonstrated that differences between the
wild type and an isogenic SpeB-negative mutant were dependent on the
growth phase of the mutant used for infection (34).
Thus, there is contrasting evidence for the role of SpeB in virulence.
This could reflect properties of the genetic background of the strains
under study or differences in the susceptibility of virulence factors
(e.g., M protein) to degradation by SpeB, potential differences in
isoenzyme forms of SpeB itself (59), or subtle differences
in the animal models (i.e., strains, site of infection, etc.) being analyzed.
Isolate 64 is an M-nontypeable isolate, and its mga regulon
has a structure of a type called pattern D (8, 24, 25). Patterns in the mga regulon are based on characteristics of
the genes clustered that reflect the evolution of this cluster by gene
duplication (8). These patterns function as genetic markers for strains with known epidemiological properties: pattern A to C
strains are highly associated with a throat tissue site of
colonization, pattern D strains are highly associated with a skin
tissue site of colonization, and pattern E strains are intermediate
(24, 25). Thus, genetic pattern may mark lineages that are
adaptive for a particular colonization site, although as yet particular properties that target a strain to a particular site are unknown.
Isolates in the pattern D group, like 64, are associated with impetigo
and invasive skin infections (10-12). Although we have not
examined the specific strains used by other investigators in previous
studies, serotype M1 and M3 strains are generally pattern A and
serotype M49 and M2 are generally pattern E. It is possible that the
genetic background of strain 64 differs in substantial ways from
backgrounds of the other strains in which SpeB expression and virulence
have previously been tested. SpeB expression may have quite different
consequences in this background and indeed appears to phase vary in the
opposite direction from strains previously examined (31).
The association described between SpeB production, capsule, and the
quantity and property of M and M-related proteins described here for
isolate 64 following exposure to biological pressures that can be
encountered during infection underscores the complexities of the
pathogenic process. Thus, the relative contributions of different
virulence factors should always be considered in a comprehensive manner, including a consideration of such variables as genetic background, capsule status, and potential for posttranslational modification by bacterial enzymes.
In this study, the large-colony SpeB phenotype forms was selected
naturally in response to biological pressures and appeared to be more
stable than the small-colony SpeB+ variant. This phase
variation may be an important component of the dynamic host-pathogen
interaction that determines whether a carrier, a local, or an invasive
infection results and may in turn be influenced by the site of initial
colonization by the bacteria.
 |
ACKNOWLEDGMENTS |
We thank Carol Hepner for typing the manuscript.
This work was supported by grant AI43474 from the National Institutes
of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Medical College of Ohio, 3055 Arlington Ave., Toledo, OH 43613-5806. Phone: (419) 383-4336. Fax: (419) 383-3002. E-mail: Mboyle{at}mco.edu.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Alberti, S.,
C. D. Ashbaugh, and M. R. Wessels.
1998.
Structure of the has operon promoter and regulation of hyaluronic acid capsule expression in group A Streptococcus.
Mol. Microbiol.
28:343-353[CrossRef][Medline].
|
| 2.
|
Ashbaugh, D. D.,
H. B. Warren,
V. J. Carey, and M. R. Wessels.
1998.
Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection.
J. Clin. Investig.
102:550-560[Medline].
|
| 3.
|
Barrett, A.,
J. Kembhavi,
A. A. Brown,
H. Kirschke,
C. G. Knight,
M. Tami, and K. Kanada.
1982.
L-trans-Epoxysuccinyl-leucylamido (4-guanidino) butane (E-64) and its analogues as inhibitors for cysteine proteinases including cathepsins B, H, and L.
Biochem. J.
2301:189-198.
|
| 4.
|
Bayer, E. A., and M. Wilchek.
1990.
Protein biotinylation.
Methods Enzymol.
185:138-160.
|
| 5.
|
Bernish, B., and I. van de Rijn.
1999.
Characterization of a two-component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production.
J. Biol. Chem.
274:4786-4793[Abstract/Free Full Text].
|
| 6.
|
Berge, A., and L. Björck.
1995.
Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins.
J. Biol. Chem.
270:9862-9867[Abstract/Free Full Text].
|
| 7.
|
Bessen, D. E., and V. A. Fischetti.
1992.
Nucleotide sequences of two adjacent M or M-like protein genes of group A streptococci: different RNA transcript levels and identification of a unique immunoglobulin A-binding protein.
Infect. Immun.
60:124-135[Abstract/Free Full Text].
|
| 8.
|
Bessen, D. E., and S. K. Hollingshead.
1994.
Allelic polymorphism of emm loci provides evidence for horizontal gene spread in group A streptococci.
Proc. Natl. Acad. Sci. USA
91:3280-3284[Abstract/Free Full Text].
|
| 9.
|
Bessen, D. E.,
L. G. Veasy,
H. R. Hill,
N. H. Augustine, and V. A. Fischetti.
1995.
Serologic evidence for class I group A streptococcal infection among rheumatic fever patients.
J. Infect. Dis.
172:1608-1611[Medline].
|
| 10.
|
Bessen, D. E.,
C. M. Sotir,
T. L. Readdy, and S. K. Hollingshead.
1996.
Genetic correlates of throat and skin isolates of group A streptococci.
J. Infect. Dis.
173:896-900[Medline].
|
| 11.
|
Bessen, D. E.,
T. R. Fiorentino, and S. K. Hollingshead.
1997.
Molecular markers for throat and skin isolates of group A streptococci.
Adv. Exp. Med. Biol.
418:537-543[Medline].
|
| 12.
|
Bessen, D. E.,
M. W. Izzo,
T. R. Fiorentino,
R. M. Caringal,
S. K. Hollingshead, and B. Beall.
1999.
Genetic linkage of exotoxin alleles and emm gene markers for tissue tropism in group A streptococci.
J. Infect. Dis.
179:627-636[CrossRef][Medline].
|
| 13.
|
Boyle, M. D. P.,
J. Hawlitzky,
R. Raeder, and A. Podbielski.
1994.
Analysis of the genes encoding two unique type IIa immunoglobulin G-binding proteins expressed by a single group A streptococcus.
Infect. Immun.
62:1336-1347[Abstract/Free Full Text].
|
| 14.
|
Burns, E. H.,
A. M. Marciel, and J. M. Musser.
1996.
Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease.
Infect. Immun.
64:4744-4750[Abstract].
|
| 15.
|
Chausee, M. S.,
D. Ajdic, and J. J. Ferretti.
1999.
The rgg gene of Streptococcus pyogenes NZ131 positively influences extracellular SPE B production.
Infect. Immun.
67:1715-1722[Abstract/Free Full Text].
|
| 16.
|
Chausee, M. S.,
E. R. Phillips, and J. J. Ferretti.
1996.
Temporal production of streptococcal erythrogenic toxin B (streptococcal cysteine proteinase) in response to nutrient depletion.
Infect. Immun.
65:1956-1959[Abstract].
|
| 17.
|
Cu, G. A.,
S. Mezzano,
J. D. Bannan, and J. B. Zabriskie.
1998.
Immunohistochemical and serological evidence for the role of streptococcal proteinase in acute post-streptococcal glomerulonephritis.
Kidney Int.
54:819-826[CrossRef][Medline].
|
| 18.
|
Dale, J. B.,
R. G. Washburn,
M. B. Marques, and M. R. Wessels.
1996.
Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci.
Infect. Immun.
64:1495-1501[Abstract].
|
| 19.
|
Elliott, S. D.
1945.
A proteolytic enzyme produced by group A streptococci with special reference to its effect on the type specific M antigen.
J. Exp. Med.
81:573-591[Abstract].
|
| 20.
|
Federle, M. J.,
K. S. McIver, and J. R. Scott.
1999.
A response regulator that represses transcription of several virulence operons in the group A streptococcus.
J. Bacteriol.
181:3649-3657[Abstract/Free Full Text].
|
| 21.
|
Heath, A.,
V. J. DiRita,
N. L. Barg, and N. C. Engleberg.
1999.
A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B.
Infect. Immun.
67:5298-5305[Abstract/Free Full Text].
|
| 22.
|
Herwald, H.,
M. Collin,
W. Werner-Esterl, and L. Björck.
1996.
Streptococcal cysteine proteinase releases kinins: a novel virulence mechanism.
J. Exp. Med.
184:1-9[Free Full Text].
|
| 23.
|
Holm, S. E.,
A. Norby,
A.-M. Bergholm, and M. Norgren.
1992.
Aspects of pathogenesis of serious group A streptococcal infections in Sweden 1988-1989.
J. Infect. Dis.
166:31-37[Medline].
|
| 24.
|
Hollingshead, S. K.,
T. L. Readdy,
D. L. Yung, and D. E. Bessen.
1993.
Structural heterogeneity of the emm gene cluster in group A streptococci.
Mol. Microbiol.
8:707-717[Medline].
|
| 25.
|
Hollingshead, S. K.,
J. Arnold,
T. L. Readdy, and D. E. Bessen.
1994.
Molecular evolution of a multigene family in group A streptococci.
Mol. Biol. Evol.
11:208-219[Abstract].
|
| 26.
|
Kapur, V.,
J. T. Maffei,
R. S. Greer,
L.-L. Li,
G. J. Adams, and J. M. Musser.
1994.
Vaccination with streptococcal extracellular cysteine protease (interleukin 1 convertase) protects mice against challenge with heterologous group A streptococci.
Microb. Pathog.
16:443-450[CrossRef][Medline].
|
| 27.
|
Kapur, V.,
M. W. Majesky,
L.-L. Li,
R. A. Black, and J. M. Musser.
1993.
Cleavage of interleukin 1 (IL-1 ) precursor to produce active IL-1 by a conserved extracellular cysteine protease from Streptococcus pyogenes.
Proc. Natl. Acad. Sci. USA
90:7676-7680[Abstract/Free Full Text].
|
| 28.
|
Kapur, V.,
S. Topouzis,
M. W. Majesky,
L. L. Li,
M. R. Hamrick,
R. J. Hamill,
J. M. Patti, and J. M. Musser.
1993.
A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin.
Microb. Pathog.
15:327-346[CrossRef][Medline].
|
| 29.
|
Kuo, C.-F.,
J.-J. Wu,
K.-Y. Lin,
P.-J. Tsai,
S.-C. Lee,
Y.-T. Jin,
H. Y. Lei, and Y.-S. Lin.
1998.
Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection.
Infect. Immun.
66:3931-3935[Abstract/Free Full Text].
|
| 30.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 31.
|
Leonard, B. A.,
M. Woischnik, and A. Podbielski.
1998.
Production of stabilized virulence factor-negative variants by group A streptococci during stationary phase.
Infect. Immun.
66:3841-3847[Abstract/Free Full Text].
|
| 32.
|
Li, Z.,
D. D. Sledjeski,
B. Kreikemeyer,
A. Podbielski, and M. D. P. Boyle.
1999.
Identification of pel, a Streptococcus pyogenes locus that affects both surface and secreted proteins.
J. Bacteriol.
181:6019-6027[Abstract/Free Full Text].
|
| 33.
|
Lukomski, S.,
E. H. Burns, Jr.,
P. R. Wyde,
A. Podbielski,
J. Rurangirwa,
D. K. Moore-Poveda, and J. M. Musser.
1998.
Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs.
Infect. Immun.
66:771-776[Abstract/Free Full Text].
|
| 34.
|
Lukomski, S.,
C. A. Montgomery,
J. Rurngirwa,
R. S. Geske,
J. P. Barrish,
G. J. Adams, and J. M. Musser.
1999.
Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice.
Infect. Immun.
67:1779-1788[Abstract/Free Full Text].
|
| 35.
|
Lukomski, S.,
S. Sreevatsan,
W. Reichardt,
A. Podbielski, and J. M. Musser.
1997.
Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains.
J. Clin. Investig.
99:2574-2580[Medline].
|
| 36.
|
Lyon, W. R.,
C. M. Gibson, and M. Caparon.
1998.
A role for trigger factor and an Rgg-like regulator in the transcription, secretion and processing of the cysteine proteinase of Streptococcus pyogenes.
EMBO J.
17:6263-6275[CrossRef][Medline].
|
| 37.
|
Malke, H.
1993.
Polymorphism of the SK gene: implications for the pathogenesis of post-streptococcal glomerulonephritis.
Zentbl. Bakteriol.
278:246-257.
|
| 38.
|
McIver, K.,
A. S. Heath,
B. D. Green, and J. R. Scott.
1995.
Specific binding of the activator Mga to promoter sequences of the emm and scpA genes in the group A streptococcus.
J. Bacteriol.
177:6619-6624[Abstract/Free Full Text].
|
| 39.
|
McIver, K.,
A. S. Heath, and J. R. Scott.
1995.
Regulation of virulence by environmental signals in group A streptococci: influence of osmolarity, temperature, gas exchange, and iron limitation on emm transcription.
Infect. Immun.
63:4540-4542[Abstract].
|
| 40.
|
McIver, K., and J. R. Scott.
1997.
Role of mga in growth phase regulation of virulence genes of the group A streptococcus.
J. Bacteriol.
179:5178-5187[Abstract/Free Full Text].
|
| 41.
|
Moses, A. E.,
M. R. Wessels,
K. Zalcman,
S. Alberti,
S. Natanson-Yaron,
T. Menes, and E. Hanski.
1997.
Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A streptococcus.
Infect. Immun.
65:64-71[Abstract].
|
| 42.
|
North, M. J.
1994.
Cysteine endopeptidases of parasitic protozoa.
Methods Enzymol.
244:523-539[Medline].
|
| 43.
|
Okada, N.,
A. P. Pentland,
P. Falk, and M. G. Caparon.
1994.
M protein and protein F act as important determinants of cell-specific tropism of streptococcus pyogenes in skin tissue.
J. Clin. Investig.
94:965-977.
|
| 44.
|
Pinkney, M.,
V. Kapur,
J. Smith,
U. Weller,
M. Palmer,
M. Glanville,
M. Messner,
J. M. Musser,
S. Bhakdi, and M. A. Chow.
1995.
Different forms of streptolysin O produced by Streptococcus pyogenes and by Escherichia coli expressing recombinant toxin: cleavage by streptococcal cysteine protease.
Infect. Immun.
63:2776-2779[Abstract].
|
| 45.
|
Podbielski, A.,
N. Schnitzler,
P. Beyhs, and M. D. P. Boyle.
1996.
M-related protein (Mrp) contributes to group A streptococcal resistance to phagocytosis by human granulocytes.
Mol. Microbiol.
19:429-441[CrossRef][Medline].
|
| 46.
|
Podbielski, A., and B. A. Leonard.
1998.
The group A streptococcal dipeptide permease (Dpp) is involved in the uptake of essential amino acids and affects the expression of cysteine protease.
Mol. Microbiol.
28:1323-1334[CrossRef][Medline].
|
| 47.
|
Podbielski, A.,
J. Hawlitzky,
T. D. Pack,
A. Flosdorff, and M. D. P. Boyle.
1994.
A group A streptococcal Enn protein potentially resulting from intergenomic recombination exhibits atypical immunoglobulin-binding characteristics.
Mol. Microbiol.
12:725-736[CrossRef][Medline].
|
| 48.
|
Raeder, R.,
R. A. Otten,
L. Chamberlin, and M. D. P. Boyle.
1992.
Functional and serological analysis of type II IgG-binding proteins expressed by pathogenic group A streptococci.
J. Clin. Microbiol.
30:3074-3081[Abstract/Free Full Text].
|
| 49.
|
Raeder, R., and M. D. P. Boyle.
1993.
Association of type II immunoglobulin G-binding protein expression and survival of group A streptococci in human blood.
Infect. Immun.
61:3696-3702[Abstract/Free Full Text].
|
| 50.
|
Raeder, R., and M. D. P. Boyle.
1993.
Association between expression of immunoglobulin G-binding proteins by group A streptococci and virulence in a mouse skin infection model.
Infect. Immun.
61:1378-1384[Abstract/Free Full Text].
|
| 51.
|
Raeder, R., and M. D. P. Boyle.
1995.
Distinct profiles of IgG-binding expression by invasive M1 serotype isolates of Streptococcus pyogenes.
Clin. Diagn. Lab. Immunol.
2:478-483[Abstract].
|
| 52.
|
Raeder, R., and M. D. P. Boyle.
1996.
Properties of IgG-binding proteins expressed by Streptococcus pyogenes isolates are predictive of invasive potential.
J. Infect. Dis.
173:888-895[Medline].
|
| 53.
|
Raeder, R.,
M. Woischnik,
A. Podbielski, and M. D. P. Boyle.
1998.
A secreted streptococcal cysteine protease can cleave a surface expressed M1 protein and alter the immunoglobulin-binding properties.
Res. Microbiol.
149:539-548[Medline].
|
| 54.
|
Reis, K. J.,
M. Yarnall,
E. M. Ayoub, and M. D. P. Boyle.
1984.
Effect of mouse passage on Fc receptor expression by group A streptococci.
Scand. J. Immunol.
20:433-439[CrossRef][Medline].
|
| 55.
|
Schrager, H. M.,
J. G. Rheinwald, and M. Wessels.
1996.
Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection.
J. Clin. Investig.
98:1954-1958[Medline].
|
| 56.
|
Schrager, H. M.,
S. Alberti,
C. Cywes,
G. J. Dougherty, and M. R. Wessels.
1998.
Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A streptococcus to CD44 on human keratinocytes.
J. Clin. Investig.
101:1708-1716[Medline].
|
| 57.
|
Schlievert, P. M.,
A. P. Assimacopoulos, and P. P. Cleary.
1996.
Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis.
J. Lab. Clin. Med.
127:13-22[CrossRef][Medline].
|
| 58.
|
Shanley, T. P.,
D. Schrier,
V. Kapur,
M. Kehoe,
J. M. Musser, and P. A. Ward.
1996.
Streptococcal cysteine protease augments lung injury induced by products of group A streptococci.
Infect. Immun.
64:870-877[Abstract].
|
| 59.
|
Stockbauer, K. E.,
L. Magoun,
M. Liu,
E. H. Burns, Jr.,
S. Gubba,
S. Renish,
X. Pan,
S. C. Bodary,
E. Baker,
J. Coburn,
J. M. Leong, and J. M. Musser.
1999.
A natural variant of the cysteine protease virulence factor of group A Streptococcus with an arginine-glycine-aspartic acid (RGD) motif preferentially binds human integrins v 3 and IIb 3.
Proc. Natl. Acad. Sci. USA
96:242-247[Abstract/Free Full Text].
|
| 60.
|
Talkington, D. F.,
B. Schwartz,
C. M. Black,
J. K. Todd,
J. Elliot,
R. F. Breiman, and R. R. Facklam.
1993.
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of toxic shock syndrome.
Infect. Immun.
61:3369-3374[Abstract/Free Full Text].
|
| 61.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 62.
|
Tsai, P. J.,
C. F. Juo,
K. Y. Lin,
Y. S. Lin,
H. Y. Lei,
F. F. Chen,
J. R. Wang, and J. J. Wu.
1998.
Effect of group A streptococcal cysteine protease on invasion of epithelial cells.
Infect. Immun.
66:1460-1466[Abstract/Free Full Text].
|
| 63.
|
Van-Heyningen, T.,
G. Fogg,
D. Yates,
E. Yanski, and M. Caparon.
1993.
Adherence and fibronectin-binding are environmentally regulated in the group A streptococcus.
Mol. Microbiol.
9:1213-1222[Medline].
|
| 64.
|
Wessels, M. R.,
A. E. Moses,
J. B. Goldberg, and T. J. DiCesare.
1991.
Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci.
Proc. Natl. Acad. Sci. USA
88:8317-8321[Abstract/Free Full Text].
|
| 65.
|
Wolf, B. B.,
C. A. Gibson,
V. Kapur,
I. M. Hussaine,
J. M. Musser, and S. L. Gonias.
1994.
Proteolytically active streptococcal pyrogenic exotoxin B cleaves monocytic cell urokinase receptor and releases an active fragment of the receptor from the cell surface.
J. Biol. Chem.
268:30682-30687.
|
| 66.
|
Yung, D.-L., and S. K. Hollingshead.
1996.
DNA sequencing and gene expression of the emm gene cluster in an M50 group A streptococcus strain virulent for mice.
Infect. Immun.
64:2193-2200[Abstract].
|
Infection and Immunity, February 2000, p. 744-751, Vol. 68, No. 2
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Graham, M. R., Virtaneva, K., Porcella, S. F., Gardner, D. J., Long, R. D., Welty, D. M., Barry, W. T., Johnson, C. A., Parkins, L. D., Wright, F. A., Musser, J. M.
(2006). Analysis of the Transcriptome of Group A Streptococcus in Mouse Soft Tissue Infection. Am. J. Pathol.
169: 927-942
[Abstract]
[Full Text]
-
Graham, M. R., Virtaneva, K., Porcella, S. F., Barry, W. T., Gowen, B. B., Johnson, C. R., Wright, F. A., Musser, J. M.
(2005). Group A Streptococcus Transcriptome Dynamics during Growth in Human Blood Reveals Bacterial Adaptive and Survival Strategies. Am. J. Pathol.
166: 455-465
[Abstract]
[Full Text]
-
Rezcallah, M. S., Boyle, M. D. P., Sledjeski, D. D.
(2004). Mouse skin passage of Streptococcus pyogenes results in increased streptokinase expression and activity. Microbiology
150: 365-371
[Abstract]
[Full Text]
-
Smith, T. C., Sledjeski, D. D., Boyle, M. D. P.
(2003). Streptococcus pyogenes Infection in Mouse Skin Leads to a Time-Dependent Up-Regulation of Protein H Expression. Infect. Immun.
71: 6079-6082
[Abstract]
[Full Text]
-
Eriksson, A., Norgren, M.
(2003). Cleavage of Antigen-Bound Immunoglobulin G by SpeB Contributes to Streptococcal Persistence in Opsonizing Blood. Infect. Immun.
71: 211-217
[Abstract]
[Full Text]
-
Jadoun, J., Eyal, O., Sela, S.
(2002). Role of CsrR, Hyaluronic Acid, and SpeB in the Internalization of Streptococcus pyogenes M Type 3 Strain by Epithelial Cells. Infect. Immun.
70: 462-469
[Abstract]
[Full Text]
-
Kansal, R. G., McGeer, A., Low, D. E., Norrby-Teglund, A., Kotb, M.
(2000). Inverse Relation between Disease Severity and Expression of the Streptococcal Cysteine Protease, SpeB, among Clonal M1T1 Isolates Recovered from Invasive Group A Streptococcal Infection Cases. Infect. Immun.
68: 6362-6369
[Abstract]
[Full Text]